This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Original articles
DuBois A, Kommoss FG, Pfisterer J, et al: Paclitaxel-induced “recall” soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses. Gynecol Oncol 60: 94–96, 1996.
Bertelli G, Cafferata MA, Ardizzoni A, et al: Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 79: 2266–2268, 1997.
Raymond E, Cartier S, Canuel C, et al: Extravasation de paclitaxel (Taxol®). Rev Méd Interne 16: 141–142, 1995.
Goodman M, Stewart I, Lydon J, et al: Use caution when managing paclitaxel and taxotere infiltrations. Oncol Nurs Forum 23: 541–542, 1996.
Bicher A, Levenback C, Burke TW, et al: Infusion site soft-tissue injury after paclitaxel administration. Cancer 76: 116–120, 1995.
Kane MP, Medina PJ, Aisner J: Vesicant reaction to paclitaxel extravasation. J Oncol Pharm Practice 4: 45, 1998.
Herrington JD, Figueroa JA: Severe necrosis,clue to paclitaxel extravasation. Pharmacotherapy 17: 163–165, 1997.
DuBois A, Fehr MK, Bochtler H, et al: Clinical course and management of paclitaxel extravasation. Oncol Rep 3: 973–974, 1996.
Ajani JA, Dodd LG, Daugherty K, et al: Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst 86: 51–53, 1994.
Meehan JL, Sporn JR: Case report of taxol administration via central vein producing a recall reaction at a site of prior taxol extravasation. J Natl Cancer Inst 86: 1250–1251, 1994.
Riedel U, Serke M, Schönfeld N, et al: Extravasation of paclitaxel (Taxol®) — clinical course. Onkologie 22: 318–320, 1999.
Shapiro J, Richardson GE: Paclitaxel-induced „recall“ soft tissue injury occuring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol 12: 2237–2238, 1994.
Panday VR, Huizing MT, Huinink WW, et al: Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 14: 418–427, 1997.
Stein ME, Drumea K, Abu-Rasmi R, et al: Taxol-induced cellulitis after extravasation: a rarely reported event. Am J Clin Oncol 20: 540, 1997.
Hidalgo M, Benito J, Colomer R, et al: Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation. J Natl Cancer Inst 88: 13–20, 1996.
Berghmans T, Klastersky J: Paclitaxel-induced cutaneous toxicity. Support Care Cancer 3: 203–204, 1995.
Bailey WL, Crump RM: Taxol extravasation: a case report. Can Oncol Nurs J 7: 96–99, 1997.
Dorr RT, Snead K, Liddil JD: Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 78: 152–156, 1996.
Secondary literature
van Gemmern R: Gewebstoxizität und Paravasatbehandlung neuer Zytostatika. Krankenhauspharmazie 17: 471–473, 1996.
Bristol-Myers Squibb, personal communication, November 1998.
Gain M, Melzer S, Meyer-Jürshof A, et al: Paclitaxel: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 3: 41, 1998.
Dorr RT: Author reply to Bertelli G, et al: Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 79: 2268–2269, 1997.
Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.
Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.
Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.
Bokemeyer C: Dermatoxizität antineoplastischer Substanzen. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1411–1426, 1999.
Berdel WE, Schmoll HJ, Michele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1689–1701, 1999.
Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.
Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.
Rogers BB: Nursing implications in the administration of paclitaxel (Taxol®). Semin Oncol Nurs 9: 11–15, 1993.
Raghavan VT, Bloomer WD, Merkel DE: Taxol and radiation recall dermatitis. Lancet 341: 1354, 1993.
Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol®). Semin Oncol 20 (Suppl 3): 1–15, 1993.
Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.
Further reading
Lorenz W, Reimann HJ, Schmal A, et al: Histamine release in dogs by Cremophor® EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 7: 63–67, 1977.
Further reading
Noone MH, McCabe MS, Denicoff AM, et al: Nursing management of the patient receiving taxol therapy. J Natl Cancer Inst Monogr 15: 149–154, 1993.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Wien
About this chapter
Cite this chapter
Mader, I., Fürst-Weger, P.E., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2003). Paclitaxel. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3710-9_41
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3710-9_41
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-3712-3
Online ISBN: 978-3-7091-3710-9
eBook Packages: Springer Book Archive